Ascendis Pharma (ASND) PT Raised to $75 at JPMorgan; 'Pipeline Updates Increase Our Confidence'

JPMorgan raised its price target on Ascendis Pharma (NASDAQ: ASND) to $75.00 (from $60.00) while maintaining a Overweight rating, following an update to the company's pipeline outlook.

Analyst Jessica Fye notes an upbeat outlook on the shares, as ASND provided a positive pipeline update coming out of ENDO 2018 where management presented data for both the TransCon hHG and PTH programs, while management continues to transform the company to an entity with multiple orphan endocrine assets in human test.

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• Yageo Corp. (2327:TT) (YAGOY) PT Lowered to NT$656 at HSBC
• American International Group (AIG) PT Raised to $89 at Piper Sandler